Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.65 |
| ▸ | ACE | P12821 | 9/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | CPA1 | P15085 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | GGT1 | P19440 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079626 | 1.00 | MME (0.65) | MMEACETSHRCNR2CPA1 | |
| SCHEMBL21883789 | 0.84 | MME (0.63) | MMEACETSHR | |
| SCHEMBL8255649 | 0.84 | MME (0.68) | MMEACETSHRCNR2GGT1 | |
| SCHEMBL5870198 | 0.84 | MME (0.88) | MMEACECPA1ACE2 | |
| SCHEMBL7222907 | 0.84 | MME (0.68) | MMEACETSHRCNR2CPA1 | |
| SCHEMBL8258027 | 0.84 | MME (0.88) | MMEACECPA1ACE2 | |
| SCHEMBL8835606 | 0.84 | MME (0.58) | MMEACECPA1ACE2 | |
| SCHEMBL8835601 | 0.84 | MME (0.58) | MMEACECPA1ACE2 | |
| SCHEMBL8248703 | 0.83 | MME (0.66) | MMEACETSHR | |
| SCHEMBL8257746 | 0.83 | MME (0.66) | MMEACETSHRCNR2CPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045619-B2 | 2-(pyrazol-3-yl)carbapenem derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-05-16 | — | — | US | disclosed |
| US-20030166923-A1 | 2-(pyrazol-3-yl)carbapenem derivatives | SMITHKLINE BEECHAM P.L.C. | 2003-09-04 | — | — | US | disclosed |
| EP-0725783-B1 | 2-(PYRAZOL-3-YL)CARBAPENEM DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2002-12-18 | — | — | EP | disclosed |
| US-20020147333-A1 | 2-(pyrazol-3-yl)carbapenem derivatives | SMITHKLINE BEECHAM P.L.C. | 2002-10-10 | — | — | US | disclosed |
| US-5612477-A | 2-(pyrazol-3-yl)carbapenem derivatives | SMITHKLINE BEECHAM P.L.C | 1997-03-18 | — | — | US | disclosed |
| US-5606051-A | 2-(pyrazol-3-yl)carbapenem derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 1997-02-25 | — | — | US | disclosed |
| EP-0725783-A1 | 2-(PYRAZOL-3-YL)CARBAPENEM DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1996-08-14 | — | — | EP | disclosed |
| WO-1995011905-A1 | 2-(PYRAZOL-3-YL)CARBAPENEM DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147333-A1 | 2-(pyrazol-3-yl)carbapenem derivatives | DPEP1, DHPS, JMJD6 | MME 875/4885ACE 831/4885TSHR 4511/4885 |
| US-20030166923-A1 | 2-(pyrazol-3-yl)carbapenem derivatives | DHPS, DPEP1, JMJD6 | MME 1239/4885ACE 1316/4885TSHR 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.